

Press Release

One Biosciences moves into The HIVE.

Villejuif, 03/03/2026 – Kadans Science Partner announces that One Biosciences, a biotechnology company specialising in precision oncology through AI-assisted single-cell analysis, has taken up residence at The HIVE, located on the Campus Grand Parc in Villejuif.

Cutting-Edge Technology to Transform Precision Medicine

One Biosciences develops innovative clinical technology solutions based on single-cell transcriptomic analysis combined with artificial intelligence. Its proprietary OneMap™ platform generates high-resolution functional tumour profiles from clinical biopsy samples, helping to inform therapeutic decisions, improve patient stratification, support therapy development and optimise clinical trials within a two-week timeframe. This approach aims to integrate the most refined molecular data directly into clinical practice to enable truly personalised medicine. Founded in 2020 as a spin-off from Institut Curie in collaboration with Home Biosciences, One Biosciences raised €15 million in Series A funding in July 2025 from leading investors, bringing its total funding to over €20 million to accelerate the clinical validation of its platforms and expand industrial partnerships. Today, the company brings together a multidisciplinary team of around twenty researchers, engineers and data specialists dedicated to advancing its technological innovations. One Biosciences is accelerated by the Paris-Saclay Cancer Cluster (PSCC) and collaborates with several of its members, including Institut Curie, Gustave Roussy, AP-HP and Sanofi.

A Strategic Base within a World-Class Scientific Ecosystem

Located on the Campus Grand Parc, in immediate proximity to the Villejuif – Gustave Roussy metro station (Lines 14 and 15), The HIVE serves as the “coffee machine” of a world-class oncology innovation ecosystem led by the PSCC, bringing together academic, clinical and industrial research. This iconic 25,000 sqm building has been designed to accommodate state-of-the-art laboratories and flexible office space, providing an ideal environment to host, structure and connect stakeholders within this innovative community.

By joining The HIVE, One Biosciences is accelerating the structuring of its laboratory activities and strengthening its capacity to collaborate with academic, clinical and industrial partners across the region and beyond.

“Moving into The HIVE is a strategic decision: it enables us to support the expansion of our teams, design bespoke laboratories to automate our processes, fully meet regulatory requirements and take a significant step forward in scaling up – all while embedding ourselves at the heart of a cutting-edge ecosystem,” explains Hedi Ben Brahim, CEO of One Biosciences.

“We are proud to welcome One Biosciences to The HIVE, which confirms both the site’s purpose and its strength as a unifying hub for the oncology community,” says Elsa Ferrard, France Director of Kadans Science Partner.

Press Release

Notes to editors

About Kadans

Kadans Science Partner is the European leader in investing in and developing science ecosystems and specialized real estate assets, with a dedicated focus on knowledge-intensive sectors. We are committed to bringing people together to address global challenges. To achieve this, we invest in, develop, and operate specialized assets designed to support and strengthen scientific clusters. Across Europe, we have built a network of clients, partner organizations, and innovative minds active in Life Sciences & Health, Agri & Food, Chemistry & Energy, and High-Tech Systems & Materials. Together, they are driven to find solutions to the global challenges we face today. Already present in more than 30 science clusters, our network continues to grow as we create new locations and support additional clusters across Europe.

Contact: e.colla@kadans.com / +33 (0) 6 17 19 41 51 / kadans.com

About the Paris-Saclay Cancer Cluster (PSCC)

The Paris-Saclay Cancer Cluster (PSCC) — a European-scale biocluster with international ambitions — accelerates innovation in oncology, making it more predictive, precise, and effective. The cluster fosters collaboration within the oncology community and provides Europe's most promising researchers with access to expertise, tools, and services, including mentorship, data, laboratory facilities, and funding opportunities.

Paris Saclay Cancer Cluster
Catherine Kuttner, Director of communication
catherine.kuttner@pscc.org / +33 (0)6 70 61 76 10

About One Biosciences

Founded in 2020 by Dr. Céline Vallot, Institut Curie, and Home Biosciences, One Biosciences is a precision oncology company transforming cancer diagnostics through AI-powered single-cell technologies. We help clinicians select optimal treatments for patients by decoding tumor heterogeneity from standard clinical samples, while enabling pharmaceutical companies to improve clinical trial outcomes. One Biosciences has partnerships with Institut Curie, Gustave Roussy, and AP-HP, and is supported by Medicen, PSCC, and Matwin.

For more information, visit: www.onebiosciences.fr

Contact: contact@onebiosciences.fr